Subject who has undergone platelet receptor GP IIb/IIIa antagonist therapy less than 48 hours prior to surgery.
Subjects must not have received chemotherapy, or undergone major surgery within 2 weeks and radiotherapy within 24 hours prior to enrollment
Subjects must not have received chemotherapy, or undergone major surgery within 2 weeks and radiotherapy within 24 hours prior to enrollment
Patients must have undergone chemotherapy and surgery for high-risk neuroblastoma prior to enrollment on trial
Patients must have undergone debulking surgery with peritonectomy and have been allowed at least 4 weeks to recover prior to receiving chemotherapy
interval of ? 14 days between end of surgery and start of protocol therapy for patients who have undergone surgery for recurrent disease.
Subjects who have undergone major surgery within 28 days of study day 1; vertebroplasty and/or kyphoplasty, which must have been performed at least 1 week prior to starting AMG-232 + KRd
Subject has undergone a prior intervention (including pleurodesis, surgery, blood patch, and pneumoperitoneum) or valve placement.
Patients who have undergone major surgery, excluding diagnostic biopsy, within 30 days (to allow for full recovery) prior to registration
Patient has undergone more than 2 debulking surgeries
The patient has undergone major surgery within 28 days prior to first dose of protocol therapy
Patients who have undergone recent surgery for recurrent or progressive tumor are eligible provided that:
Has undergone prior surgery at the tumor site or the index tumor has undergone previous surgery or ablation treatment
Subjects having undergone a major surgery within the last 6 weeks
Patients who have undergone major surgery within 14 days
Have undergone major surgery or received any investigational therapy in the 4 weeks prior to study entry.
Patients who have undergone major surgery within 1 month prior to screening.
Patients having undergone major surgery less than 4 weeks prior to enrollment or have not fully recovered from prior surgery
Patients who have undergone major surgery (including open biopsy, thoracotomy, organ resection, exploratory laparotomy, arteriovenous grafts) < 28 days prior to enrollment will have bevacizumab dosing delayed
Have undergone major surgery within 28 days prior to receiving study drugs.
Patients who have undergone radiation within the past 4 weeks
Patients should NOT have undergone any prior cancer directed surgery (exploration, debulking, etc), with the exception of a minor procedure such as biopsy or cytology specimen
Have undergone a lumpectomy or mastectomy
PATIENT ONLY: Patients must be within 1 month of initiating or having undergone any type of cancer treatment (i.e., surgery, radiotherapy, chemotherapy)
Patients must have previously undergone or plan to undergo thyroidectomy; for those patients who have previously undergone surgery, pre-operative labs, including complete blood cell count with differential must be available
EXCLUSION - STUDY 1: Undergone surgery in the last 6-8 weeks
Undergone laser corrective eye surgery in the past 30 days
Patients who have not undergone any surgical treatment for their cancer
Patients who have not undergone surgery in the past 6 months; patients may have had neoadjuvant chemotherapy prior to surgery
Has undergone prior ablation treatment of the index tumor
Have undergone surgical debulking
Previously undergone major pelvic surgery
Patients who have undergone a prior tubal ligation will be eligible
Have undergone a lumpectomy or mastectomy
Subjects who have undergone bariatric surgery are not eligible
Subjects who have undergone major surgery ? 2 weeks prior to starting study drugs.
Patients who have undergone surgery within 24 hours prior to the study sonographic examination
Subjects who have undergone prior radioembolization
Patients who have undergone surgery within 24 hours prior to the study sonographic examination
Patients who have not undergone a visit for cancer surveillance since 2009